Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus SSRI in severe major depressive disorder
ISRCTN19313268Phase 3Completed
- Sponsor
- Servier
- Start
- Oct 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Hamilton Depression Rating Scale total score. Started Oct 2005; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN19313268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19313268.